Hematology-American Society of Hematology Education Program

Papers
(The TQCC of Hematology-American Society of Hematology Education Program is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?64
Your chemo is no good here: management of high-risk MCL63
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?56
Neurological manifestations of MGUS37
Anticoagulation at the end of life: whether, when, and how to treat36
On the horizon: upcoming new agents for the management of ITP36
Labor and delivery: DIC, HELLP, preeclampsia34
Mastocytosis demystified32
Hematopoietic cell transplantation for sickle cell disease: updates and future directions31
Inpatient recognition and management of HLH30
Bispecific antibody therapies27
Diagnosis and therapeutic decision-making for the neutropenic patient26
Has PD-1 blockade changed the standard of care for cHL?25
Recognizing, defining, and managing CAR-T hematologic toxicities25
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma24
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma23
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL23
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease22
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors22
Divergent paths: management of early relapsed follicular lymphoma22
New approaches to tackle cytopenic myelofibrosis21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease21
MGCS: where do we stand today?20
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events20
Optimizing outcomes in secondary AML19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?19
Fitness and frailty in myeloma19
How to recognize and manage COVID-19-associated coagulopathy18
Selecting initial therapy in CLL18
How to assess hemostasis in patients with severe liver disease18
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia18
BV and beyond: how to incorporate novel agents into PTCL management18
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies18
Troubleshooting heparin resistance18
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores17
Increasing access to allogeneic hematopoietic cell transplant: an international perspective17
Consumptive coagulopathy in the ICU17
How to diagnose and manage antiphospholipid syndrome17
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?17
Hemophilia gene therapy: ushering in a new treatment paradigm?17
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity17
How to manage hemostasis in patients with liver disease during interventions17
Running interferon interference in treating PV/ET: meeting unmet needs17
Incorporating novel agents into frontline treatment of Hodgkin lymphoma17
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation16
Hematology 2022—what is complete HLA match in 2022?16
Management of TKI-resistant chronic phase CML16
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?16
Special considerations in GI bleeding in VWD patients16
Demystifying autoimmune HIT: what it is, when to test, and how to treat15
Management of limited-stage Hodgkin lymphoma15
Management of marginal zone lymphomas14
Atypical CML: diagnosis and treatment14
How to manage bleeding disorders in aging patients needing surgery14
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies14
What to use to treat AML: the role of emerging therapies14
Managing therapy-associated neurotoxicity in children with ALL14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment13
Infectious complications and vaccines13
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy13
Thrombosis questions from the inpatient wards13
Approaches to management of HIT in complex scenarios, including cardiac surgery13
CNS prophylaxis in aggressive B-cell lymphoma12
When does a PNH clone have clinical significance?12
Nontransplant treatment approaches for myeloid neoplasm with mutated TP5312
Organ function indications and potential improvements following curative therapy for sickle cell disease12
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?12
Alloimmunization and hyperhemolysis in sickle cell disease12
Lower risk but high risk12
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products12
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment12
Transplant in AML with measurable residual disease: proceed or defer?12
Treatment of VTE in the thrombocytopenic cancer patient11
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease11
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?11
Thrombocytopenia in pregnancy11
Pegylated interferon: the who, why, and how11
What makes a pediatric or young adult patient an appropriate transplant candidate?11
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms11
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?11
Cytoreduction for ET and PV: who, what, when, and how?11
What is the ideal approach—doublet, triplet, or quadruplet(s)?11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective10
Clinical manifestations of telomere biology disorders in adults10
Whom should we treat with novel agents? Specific indications for specific and challenging populations10
Ph− ALL: immunotherapy in upfront treatment10
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax10
Next-generation therapy for lower-risk MDS10
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation10
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?10
What else do I need to worry about when treating graft-versus-host disease?9
Should we use bisphosphonates to treat bone complications in sickle cell disease?9
Porphyria cutanea tarda: a unique iron-related disorder9
Managing side effects: guidance for use of immunotherapies in multiple myeloma9
Novel therapies upon failure of HMA plus venetoclax9
Sequencing bispecific antibodies and CAR T cells for FL9
Approach to the patient with suspected hypereosinophilic syndrome9
Stem cell transplantation for ALL: you've always got a donor, why not always use it?9
Frontline treatment in CLL: the case for time-limited treatment9
The role of stem cell transplant (auto and allo) in PTCL and CTCL9
IV iron formulations and use in adults9
0.061456918716431